Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE) is a Healthcare stock tracked by StreetAlpha. It last closed at $14.77 on Sep 24. RARE reports earnings on Tue, Nov 3, 2026. The average 12-month price target from 16 analysts is $27.56 (+86.6% from the last close), with a high of $40.00 and a low of $16.00. Analyst consensus is Buy, based on the latest ratings from 16 firms (10 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in RARE, 60% of them bullish and 40% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 16 analysts who set a price target on RARE in the past 90 days. The average target is $27.56, with a high of $40.00 and a low of $16.00, compared with the last close of $14.77.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 21 | Evercore ISI Group | Target raised | Hold | $16 → $18 |
| Sep 21 | Barclays | Target raised | Buy | $32 → $35 |
| Sep 18 | Morgan Stanley | Maintained | Hold | $20 |
| Sep 18 | Citigroup | Target raised | Buy | $28 → $32 |
| Sep 18 | Canaccord Genuity | Target raised | Buy | $37 → $39 |
Whale Options Flow
90DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RARE is in one of them and how their past RARE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RARE in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.